Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Rona Yaeger, Jared Weiss, Meredith Pelster, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 44-54
Open Access | Times Cited: 288

Showing 26-50 of 288 citing articles:

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer
Sander Mertens, Maarten A. Huismans, Carla S. Veríssimo, et al.
Cell Reports (2023) Vol. 42, Iss. 4, pp. 112324-112324
Open Access | Times Cited: 35
Update on Emerging Therapies for Advanced Colorectal Cancer
Olatunji B. Alese, Christina Wu, William J. Chapin, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 27
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 24
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Stefania Napolitano, Giulia Martini, Davide Ciardiello, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 7, pp. 664-676
Closed Access | Times Cited: 13
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Nadia Saoudi, Javier Ros, Iosune Baraibar, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 412-412
Open Access | Times Cited: 12
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 12
Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer
Alice Boilève, Jérôme Cartry, Negaar Goudarzi, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 961-976.e13
Open Access | Times Cited: 11
Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients
Izabela Ciepiela, Magdalena Szczepaniak, Przemysław Ciepiela, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Priyadarshini Pathak, Gloria Chan, Dustin A. Deming, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 10
Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
Qian Chen, Weihao Lin, Xiao-xiang Zhou, et al.
Pharmacological Research (2024) Vol. 200, pp. 107060-107060
Open Access | Times Cited: 9
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
Ashenafi Bulle, Peng Liu, Kuljeet Seehra, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi‐Targeting Drugs Through Materials Engineering: A Possible Future Scenario
Marianna Puzzo, Marzia De Santo, Catia Morelli, et al.
Small Science (2024) Vol. 4, Iss. 8
Open Access | Times Cited: 9
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 9
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Biological insights in non-small cell lung cancer
Rafael Rosell, Anisha Jain, Jordi Codony‐Servat, et al.
Cancer Biology and Medicine (2023), pp. 1-19
Open Access | Times Cited: 19
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
John H. Strickler, Takayuki Yoshino, Kendall Stevinson, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. e981-e994
Open Access | Times Cited: 19
Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications
Nadia Saoudi, Francesc Salvà, Javier Ros, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4020-4020
Open Access | Times Cited: 19
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Cen Liu, Danyang Ye, Hongliu Yang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 18
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Giorgio Patelli, Gianluca Mauri, Federica Tosi, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4530-4539
Open Access | Times Cited: 17
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
Laura Roazzi, Giorgio Patelli, Katia Bencardino, et al.
Clinical Colorectal Cancer (2024) Vol. 23, Iss. 4, pp. 295-308
Closed Access | Times Cited: 7
Advances in tumor vascular growth inhibition
Keyong Zhang, Yuanyuan Shi, Ze Jin, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 9, pp. 2084-2096
Closed Access | Times Cited: 7

Scroll to top